Supplement Figure 1: Competitive Inhibition of CYP11B2 by binding of Torasemide to the Heme Binding Site of CYP11B2 through its Nitrogen Ring

Structural formula of (A) fadrozol, a competitive CYP11B2 inhibitor, (B) torasemide and (C) furosemide. (D) Active site of CYP11B2 (heme and substrate - binding site), binding of a torasemide by its nitrogen ring.
Supplement Figure 2: Quantification and representative western blots of connective tissue growth factor (CTGF) protein expression related to tubulin in atrial HL-1 myocytes stimulated with angiotensin II (Ang, 1µM; 3 hours) and pre-incubated with or without the CYP11B2 specific inhibitor SL 242 (1µM; 24 hours), n=8, *p<0.05 vs. control (C); #p<0.05 vs. Ang.